DM-101PX
/ Desentum
- LARVOL DELTA
Home
Next
Prev
1 to 18
Of
18
Go to page
1
November 29, 2025
Study to Evaluate Safety and Efficacy of DM-101PX in Adults With Birch Pollen Allergy
(clinicaltrials.gov)
- P2 | N=100 | Recruiting | Sponsor: Desentum Oy
New P2 trial • Allergic Rhinitis • Allergy • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology
October 08, 2025
RANDOMIZED, PLACEBO CONTROLLED PHASE 1B TRIAL OF APL-18881, A NOVEL FGF21 AND GLP-1 BISPECIFIC DUAL RECEPTOR AGONIST, EVALUATING MEASURES OF METABOLIC AND LIVER HEALTH IN PATIENTS WITH TYPE 2 DIABETES AFTER 5 WEEKS OF TREATMENT
(AASLD 2025)
- " HEC88473-DM-101 was a single-centre, randomized, double-blind, placebo-controlled Phase 1b trial to evaluate the safety, tolerability, PK, and PD of APL-18881. APL-18881 demonstrated robust dose-dependent improvement in measures of metabolic and liver health in a Phase 1b MAD trial in participants with T2D after 5 weeks of treatment. The effects observed on MRI-PDFF and liver stiffness support the potential of APL-18881 to be an effective therapeutic in SLD."
Clinical • P1 data • Diabetes • Hepatology • Metabolic Disorders • Type 2 Diabetes Mellitus • FGF21
March 26, 2025
Subcutaneous AIT with a thermosensitive hydrogel formulation containing genetically engineered Bet v 1 is safe and induces a strong protective immune response in birch pollen allergic patients
(EAACI 2025)
- "Moreover, the immune response was shown to block Bet v 1-mediated basophil activation and it sustained for at least 6 months after treatment. Conclusion The approach to design highly efficient allergy vaccines based on subtly modified allergens formulated with a thermosensitive hydrogel is endorsed by clinical results showing that short-course treatment with DM-101PX is safe, well tolerated, and able to induce a strong and functional immune response."
Clinical • Immunology
March 26, 2025
Detection of blocking antibodies using a basophil activation test in sera from allergic patients treated with investigational birch pollen allergy vaccine DM-101PX
(EAACI 2025)
- "No reduction in activation was seen in the BA-BAT with post-treatment sera from patients that had been treated with placebo. Conclusion The induction of high levels of Bet v 1-IgG4 in patients treated with DM-101PX was found to be associated with a strong potential to block Bet v 1-mediated basophil activation, which suggests that the IgG4 antibodies induced by DM-101PX can functionally inhibit IgE-mediated activation of effector cells."
Clinical • Allergy • Immunology • CD63
April 02, 2025
Desentum Reports Strong Safety and Immunological Data From Phase 1 Clinical Study With Investigational Birch Pollen Allergy Vaccine DM-101PX
(Businesswire)
- P1 | N=30 | NCT06037148 | Sponsor: Desentum Oy | "Desentum Oy...announces positive clinical data with birch pollen allergy vaccine DM-101PX. The short-course treatment was found to be safe and well tolerated in birch pollen allergic patients and to induce a very strong and sustained allergen-specific IgG4 response....The treatment induced a robust allergen-specific IgG4 response, which was found to be associated with effective blocking of IgE-mediated basophil activation. Elevated allergen-specific IgG4 levels and IgE-blocking activity were still detectable in patients’ blood samples at a follow-up visit 28–37 weeks after completion of the treatment indicating that DM-101PX induces a sustained immune response, which is expected to protect against allergic symptoms....'Based on the positive data from Phase 1, we have decided to advance the product into Phase 2 clinical trials in which the clinical effects of treatment with DM-101PX will be investigated.'"
P1 data • Allergy • Immunology
December 17, 2024
Optimization of Naringin Extraction, Synthesis of Dihydrochalcone and Its Effects on Reducing Blood Lipid Levels In Vitro.
(PubMed, Molecules)
- "Naringin was purified to obtain naringin-refined products using DM101 macroporous adsorption resin...We measured the effects of different concentrations of naringin dihydrochalcone on intracellular lipids in denatured HepG2 cells and further validated the lipid-lowering effect of naringin at the cellular level. The results showed that naringin dihydrochalcone has a potential application in functional foods for lowering blood lipids."
Journal • Preclinical
April 06, 2024
Poloxamer formulation for allergen immunotherapy reduces systemic allergic reactions in a mouse model
(EAACI 2024)
- "Conclusion Formulation of DM-101 with P338 reduces its potential to induce systemic allergic reactions and allows the application of higher doses of DM-101 in Bet v 1-sensitized mice. Treatment of Bet v 1-sensitized mice with a high dose of poloxamer-formulated DM-101 also showed a favorable immune response as it did not induce Bet v 1-sIgE and it prevented the induction of pro-inflammatory cytokines upon a challenge with birch pollen extract."
Preclinical • Allergy • Immunology
April 06, 2024
Development of a thermosensitive poloxamer formulation designed to provide a controlled release of the active pharmaceutical ingredient in birch pollen allergen immunotherapy
(EAACI 2024)
- "Conclusion The measured characteristics support the use of DM-101PX as an injectable solution for subcutaneous allergen immunotherapy. The poloxamer formulation supports the encapsulation of the allergen into a hydrogel at body temperature and the controlled release of the allergen in its native form upon injection."
Immunology
March 28, 2024
A Monocarbonyl Curcuminoid Derivative Inhibits the Activity of Human Glutathione Transferase A4-4 and Chemosensitizes Glioblastoma Cells to Temozolomide.
(PubMed, Pharmaceuticals (Basel))
- "Among the curcumin derivatives studied, three proved to be the most potent inhibitors, in the order DM151 > DM101 > DM100, with IC50 values of 2.4 ± 0.1 μM, 12.7 ± 1.1 μΜ and 16.9 ± 0.4 μΜ, respectively. The results revealed that DM151 displays considerably higher cytotoxicity against both glioblastoma cell lines, while the glioblastoma cytotoxicity of DM148 was very limited. Furthermore, low and non-toxic doses of DM151 sensitized U-251 MG cells to the first-line glioblastoma chemotherapeutic temozolomide (TMZ), allowing us to propose for the first time that hGSTA4-4 inhibitors may be attractive therapeutic partners for TMZ to optimize its clinical effect in glioblastoma chemotherapy."
Journal • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor
March 25, 2024
Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants
(clinicaltrials.gov)
- P1 | N=30 | Completed | Sponsor: Desentum Oy | Active, not recruiting ➔ Completed
Trial completion • Allergy • Immunology
December 19, 2023
Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants
(clinicaltrials.gov)
- P1 | N=30 | Active, not recruiting | Sponsor: Desentum Oy | Recruiting ➔ Active, not recruiting
Enrollment closed • Allergy • Immunology
September 15, 2023
Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: Desentum Oy
New P1 trial • Allergy • Immunology
February 26, 2023
Optimisation of the Extraction Process of Naringin and Its Effect on Reducing Blood Lipid Levels In Vitro.
(PubMed, Molecules)
- "DM101 macroporous adsorption resin was used to purify naringin...In vitro determination of the lipid-lowering activity of naringin was also conducted. These results showed that naringin has potential applications as a functional food for lowering blood lipid levels."
Journal • Preclinical
June 04, 2021
Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy
(clinicaltrials.gov)
- P1; N=27; Completed; Sponsor: Desentum Oy; Active, not recruiting ➔ Completed
Clinical • Trial completion • Allergy • Immunology
March 22, 2021
Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy
(clinicaltrials.gov)
- P1; N=27; Active, not recruiting; Sponsor: Desentum Oy; Recruiting ➔ Active, not recruiting
Clinical • Enrollment closed • Allergy • Immunology
November 17, 2020
Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy
(clinicaltrials.gov)
- P1; N=27; Recruiting; Sponsor: Desentum Oy; Suspended ➔ Recruiting; N=46 ➔ 27; Trial completion date: Aug 2020 ➔ Aug 2021; Trial primary completion date: Jul 2020 ➔ Jul 2021
Clinical • Enrollment change • Enrollment open • Trial completion date • Trial primary completion date • Allergy • Immunology
April 03, 2020
Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy
(clinicaltrials.gov)
- P1; N=46; Suspended; Sponsor: Desentum Oy; Recruiting ➔ Suspended
Clinical • Trial suspension
February 12, 2020
Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy
(clinicaltrials.gov)
- P1; N=46; Recruiting; Sponsor: Desentum Oy
Clinical • New P1 trial
1 to 18
Of
18
Go to page
1